SCHEMBL16446605

SCHEMBL16446605

CCOC(=O)Cc1ccc(N2CCc3c(C)nc(-c4ccc(OC)c(Cl)c4)nc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.51
▸ KDM4E B2RXH2 3/20 0.41
▸ MAPT P10636 3/20 0.41
▸ PDE4D Q08499 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ KMT2A Q03164 3/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP2C19 P33261 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ PTGS2 P35354 1/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ RAD52 P43351 1/20 0.36
▸ GPR52 Q9Y2T5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446387 0.92 PDE4B (0.61) PDE4BKDM4EMAPTPDE4DHRH4
SCHEMBL16446831 0.91 PDE4B (0.53) PDE4BKDM4EMAPTPDE4DALDH1A1
SCHEMBL16446693 0.90 PDE4B (0.64) PDE4BKDM4EMAPTPDE4DALDH1A1
SCHEMBL16446595 0.83 PDE4B (0.66) PDE4BPDE4DHRH4PTGS2GPR52
SCHEMBL16446717 0.82 PDE4B (0.75) PDE4BKDM4EMAPTPDE4DLMNA
SCHEMBL16446333 0.81 MAPT (0.47) KDM4EMAPTALDH1A1NPC1LMNA
SCHEMBL16446508 0.79 PDE4B (0.60) PDE4BKDM4EMAPTPDE4DPTGS2
SCHEMBL16446551 0.74 PDE4B (0.42) PDE4BKDM4EMAPTALDH1A1NPC1
SCHEMBL16446603 0.74 MTNR1A (0.37) PDE4BMAPTPDE4DHRH4PTGS2
SCHEMBL16447061 0.73 PDE4B (0.46) PDE4BKDM4EPDE4DALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885KDM4E 1607/4885MAPT 3104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback